CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
about
Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell linesCD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.A 40-year-old man with recurrent fainting, hypotension, lower limb edema and oliguria with body weight gain and secondary erythrocytosis.Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.Cellular immune dysfunction in immune thrombocytopenia (ITP).Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.Rituximab in primary Sjögren's syndrome: a ten-year journey.B-lymphocyte-mediated delayed cognitive impairment following stroke.A small CD11b(+) human B1 cell subpopulation stimulates T cells and is expanded in lupusInduction of Th17 cell differentiation by B-1 cells.An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.The evolving pharmacotherapy of pulmonary fibrosis.Epratuzumab for systemic lupus erythematosus.The human counterpart of mouse B-1 cells.Response of patients with refractory myasthenia gravis to rituximab: a retrospective study.Immunological evaluation of predicted linear B-cell epitopes of human CD20 antigen.Rituximab in severe, treatment-refractory interstitial lung disease.Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.Subacute cutaneous lupus erythematosus in the course of rheumatoid arthritis: a relationship with TNF-α antagonists and rituximab therapy?Expression of CD markers' in immune thrombocytopenic purpura: prognostic approaches.Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
P2860
Q28742585-9236E328-0893-46D4-BAE7-986C10D99FFEQ30388433-BDC26F98-7CBC-4E50-A6AA-D9D1F2FB34B1Q33160493-70393B64-A28B-41B2-95CD-5379923992B8Q33396902-6E0D002A-57B5-4CE2-844F-1DFA920DEDF4Q33409710-D1340FDC-007B-42AA-9C95-A1910E19C0EFQ33802001-5FAC9E46-2DE6-4A1C-B9D7-D9AE1167C59EQ34432465-83E9654E-CF56-4F17-A35E-1264AA4FA607Q35044819-A974935C-C525-471F-B4EF-3A8A4DDE3A11Q35627702-EFE9055E-D664-4A8E-8AEC-4B16870976A0Q36223923-698046CE-AB51-4654-B652-E5994C8BA305Q37418292-90D47333-4F50-4DE7-946B-18DC5FC9A78DQ38069617-3A0DCC3A-F892-467A-AAFF-36BD3C98986FQ38095865-36FAFBF2-BF87-4901-BEFB-B39B816D3CADQ38491162-BC3681A0-1C9F-47B0-85CB-8F284D07AAF7Q38633453-BCB19EA6-B6C9-4555-8224-6E4103931CEAQ39166301-E0BD8286-C33F-4441-91B0-FF5FCDB42242Q39305650-DA551FD2-E8B3-44E5-A322-F0772DE5D9F6Q39365604-EB6B51AC-25BE-4892-9A1A-83F8776E5DC0Q45865616-761A83E5-D63B-4A35-9F5C-74EEE841DF75Q46252749-217BA9F5-8140-48C8-A38C-AF128F7C67A3Q47727224-A3C62B77-F74C-487F-BB77-C2CF56F3EE33Q52880098-2CD2159D-C13C-4AC7-A720-EFE449D07262
P2860
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
@en
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
@nl
type
label
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
@en
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
@nl
prefLabel
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
@en
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
@nl
P2860
P1476
CD20-depleting therapy in autoimmune diseases: from basic research to the clinic
@en
P2093
P2860
P304
P356
10.1111/J.1365-2796.2009.02207.X
P407
P577
2010-03-01T00:00:00Z